FDA Leadership After Marty Makary: What Biotech Needs Next
FDA instability. AI in clinical trials. China overtaking the United States in biotech development.
Following news that Marty Makary has stepped down as FDA commissioner, questions around regulatory stability, scientific leadership, and the future of biotech innovation are back in focus.
This week on the Making Medicine Podcast, John Stanford examines what the FDA needs most during periods of leadership transition: scientific credibility, regulatory expertise, and a stable, predictable process for developing new medicines.
Recorded before the latest leadership announcement, this episode…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.